S. Paul and J. D. Lelièvre, Le mécanisme d'action des vaccins, le rôle des adjuvants, Collège des enseignants d'immunologie. Immunologie fondamentale et immunopathologie. Paris, 2 e édition, pp.255-62, 2018.

M. M. Alleman, R. Chitale, and C. C. Burns, Vaccine-Derived Poliovirus Outbreaks and Events -Three Provinces, Democratic Republic of the Congo, MMWR Morb Mortal Wkly Rep, vol.67, issue.10, pp.300-305, 2017.

R. K. Gherardi, M. Coquet, and P. Cherin, Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM), Lancet, vol.352, issue.9125, pp.347-52, 1998.

F. J. Authier, S. Sauvat, and C. Christov, AlOH3-adjuvanted vaccineinduced macrophagic myofasciitis in rats is influenced by the genetic background, Neuromuscul Disord, vol.16, issue.5, pp.347-52, 2006.
URL : https://hal.archives-ouvertes.fr/in2p3-00068499

Z. Khan, C. Combadiere, and F. J. Authier, Slow CCL2-dependent translocation of biopersistent particles from muscle to brain, BMC Med, vol.11, p.99, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00807777

B. Autran, J. Beytout, and D. Floret, Aluminium et vaccins, rapport HAS, 11 juillet 2013. rapport HAS, 2013.

A. C. Berical, D. Harris, D. Cruz, and C. S. , Pneumococcal Vaccination Strategies. An Update and Perspective, vol.13, pp.933-937, 2016.

C. I. Barker and M. D. Snape, Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action, Lancet Infect Dis, vol.14, issue.3, pp.227-265, 2014.

L. Wessel, Vaccine myths, Science, vol.356, issue.6336, pp.368-72, 2017.

A. Hviid, J. V. Hansen, and M. Frisch, Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study, Ann Intern Med, 2019.

L. Houezec and D. , Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination, Immunol Res, vol.60, issue.2-3, pp.219-244, 2014.

M. A. Hernan, S. S. Jick, and M. J. Olek, Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study, Neurology, vol.63, issue.5, pp.838-880, 2004.

, Vaccins contre l'hépatite B : résumé des débats de la comission nationale de pharmacovigilance, AFSSAPS, 2004.

H. C. Lehmann, H. P. Hartung, and B. C. Kieseier, Guillain-Barre syndrome after exposure to influenza virus, Lancet Infect Dis, vol.10, issue.9, pp.643-51, 2010.

C. Vellozzi, S. Iqbal, and K. Broder, Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence, Clin Infect Dis, vol.58, issue.8, pp.1149-55, 2014.

J. L. Montastruc, G. Durrieu, and O. Rascol, Pandemrix degrees, (H1N1)v influenza and reported cases of narcolepsy, Vaccine, vol.29, issue.11, p.2010, 2011.

H. Nohynek, J. Jokinen, and M. Partinen, AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland, PLoS One, vol.7, issue.3, p.33536, 2012.

M. Partinen, O. Saarenpaa-heikkila, and I. Ilveskoski, Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland, PLoS One, vol.7, issue.3, p.33723, 2012.

. Department, . Health, and . Ireland, Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010: final report of national narcolepsy study steering committee

, Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations -results of a case inventory study by the MPA in Sweden during, Medical, 2009.

Y. Dauvilliers, I. Arnulf, and M. Lecendreux, Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France, Brain, vol.136, pp.2486-96, 2013.

O. Vaarala, A. Vuorela, and M. Partinen, Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk, PLoS One, vol.9, issue.12, p.114361, 2014.

C. S. Waddington, W. T. Walker, and C. Oeser, Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study, BMJ, vol.340, p.2649, 2010.

A. K. De-la-herran-arita, B. R. Kornum, and J. Mahlios, CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy, Sci Transl Med, vol.5, issue.216, pp.216-176, 2013.

A. Auvinen, T. Hakulinen, and F. Groves, Haemophilus influenzae type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland, Br J Cancer, vol.83, issue.7, pp.956-964, 2000.

F. D. Groves, G. Gridley, and S. Wacholder, Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA, Br J Cancer, vol.81, issue.1, pp.175-183, 1999.

X. Ma, M. B. Does, and C. Metayer, Vaccination history and risk of childhood leukaemia, Int J Epidemiol, vol.34, issue.5, pp.1100-1109, 2005.

S. H. Soegaard, K. Rostgaard, and K. Schmiegelow, Childhood vaccinations and risk of acute lymphoblastic leukaemia in children, Int J Epidemiol, vol.46, issue.3, pp.905-918, 2017.

S. Swaminathan, L. Klemm, and E. Park, Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia, Nat Immunol, vol.16, issue.7, pp.766-74, 2015.